SEP 10, 2026 · PHASE 2 TRIAL
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
ClinicalTrials.gov
This is a Phase 2 trial registry record with no posted results; the study is active but not recruiting, so outcomes remain unreported and cannot be assessed.
Reported
Sample size83
PhasePhase 2
Primary endpointProgression-Free Survival (PFS) from random…